Exchange Traded Concepts LLC Boosts Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Exchange Traded Concepts LLC boosted its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 9.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 41,866 shares of the company’s stock after purchasing an additional 3,740 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Autolus Therapeutics were worth $152,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics in the 2nd quarter worth approximately $43,000. Daiwa Securities Group Inc. grew its position in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new position in shares of Autolus Therapeutics in the 3rd quarter worth approximately $91,000. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics in the 1st quarter worth approximately $100,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of Autolus Therapeutics in the 1st quarter worth approximately $108,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $4.52 on Tuesday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -3.77 and a beta of 2.04. The stock has a 50 day moving average of $3.96 and a 200-day moving average of $4.10. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics plc has a 52 week low of $2.21 and a 52 week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.